Markets:

Overview

News

Currencies

International

Treasuries

Vivani Medical, Inc. - Common Stock (NQ:VANI)

1.503 -0.007 (-0.44%)

Streaming Delayed Price Updated: 9:34 AM EDT, Apr 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Vivani Medical, Inc. - Common Stock

< Previous 1 2 3 Next >

Vivani Medical Inc (NASDAQ:VANI) Reports Q4 2025 Results, Advances Semaglutide Implant to Phase 1 ↗

March 26, 2026

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 17, 2025

Via Benzinga

Which stocks are experiencing notable movement on Wednesday? ↗

September 17, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Discover the top movers in Wednesday's pre-market session. ↗

September 17, 2025

Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 17, 2025

Via Benzinga

EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data ↗

August 05, 2025

Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose.

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 13, 2025

Via Benzinga

EXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs ↗

April 15, 2025

Vivani Medical and Okava expand GLP-1 therapy research to dogs, aiming to advance long-acting treatments for cardiometabolic conditions.

Via Benzinga

Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment Soars ↗

March 26, 2025

The company said on Wednesday that a single administration of the implant in healthy rats resulted in 20% lower body weight through a 91-day treatment period as compared to a control group that...

Via Stocktwits

EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing ↗

March 26, 2025

Vivani Medical's NPM-139 semaglutide implant showed steady drug release and nearly 20% weight loss in preclinical studies, supporting long-term weight management.

Via Benzinga

EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity ↗

March 13, 2025

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025.

Via Benzinga

EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value ↗

March 12, 2025

Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while focusing on its drug implants.

Via Benzinga

EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia ↗

December 19, 2024

Vivani Medical launches first-in-human trial of its exenatide implant in Australia, aiming to support chronic weight management with innovative GLP-1 technology.

Via Benzinga

EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia ↗

September 26, 2024

Vivani Medical receives approval for the first human trial of its GLP-1 obesity implant in Australia. The LIBERATE-1 trial will assess safety, tolerability, and weight loss outcomes, with data expected...

Via Benzinga

EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity ↗

September 04, 2024

Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical trial is...

Via Benzinga

VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024 ↗

August 13, 2024

VANI stock results show that Vivani Medical beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Pineapple Financial And 1 Other Stock Under $1 Insiders Are Buying ↗

August 05, 2024

Via Benzinga

Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying ↗

August 02, 2024

Via Benzinga

EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year ↗

July 11, 2024

Vivani Medical plans to start the first clinical study of the NPM-115 program in Australia in Q4 2024. The study will evaluate a 6-month GLP-1 implant for chronic weight management in obese or...

Via Benzinga

Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 13, 2024

Via Benzinga

Why GLP-1 Developer Vivani Medical's Stock Is Climbing ↗

June 13, 2024

Vivani Medical shares are trading higher Thursday after the company announced the FDA cleared the Investigational New Drug application and lifted the clinical hold on NPM-119.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 13, 2024

Via Benzinga

EXCLUSIVE: Vivani Medical's Type 2 Diabetes Treatment NPM-119 Subdermal Implant's NDA Gains FDA Clearance For Clinical Use ↗

June 13, 2024

Vivani Medical cleared FDA for NPM-119 trial in type 2 diabetes. LIBERATE-1 will assess safety, tolerability, & pharmacokinetics. NPM-115 & NPM-139 also in development for weight management.

Via Benzinga

EXCLUSIVE: Vivani Medical Highlights Weight Loss Data For GLP-1 Implant Supporting Potential Veterinary Use ↗

May 28, 2024

Vivani Medical announced proof-of-concept data for a subdermal exenatide implant designed for feline obesity and diabetes, which was published in BMC Veterinary Research.

Via Benzinga

VANI Stock Earnings: Vivani Medical Meets EPS for Q1 2024 ↗

May 13, 2024

VANI stock results show that Vivani Medical met analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

VANI Stock Earnings: Vivani Medical Beats EPS for Q4 2023 ↗

March 26, 2024

VANI stock results show that Vivani Medical beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 04, 2024

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 04, 2024

Via Benzinga

Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 01, 2024

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.